FIXED COMBINATION OF THE CALCIUM CHANNEL BLOCKER LERCANIDIPINE AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR ENALAPRIL: POSSIBILITY OF USAGE
https://doi.org/10.20996/1819-6446-2013-9-2-177-182
Abstract
Data on the updated approach to the choice of two-component antihypertensive combinations for different clinical situations are presented. Advantages and indications for combination of an angiotensin converting enzyme (ACE) inhibitor and dihydropyridine calcium antagonist are considered. Data on the efficacy and safety of the combination of calcium antagonist of the third generation, lercanidipine, and ACE inhibitor, enalapril, are presented.
About the Authors
O. D. Ostroumova
Moscow State University of Medicine and Dentistry;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
I. I. Kopchenov
Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
References
1. National guidelines for the diagnosis and treatment of hypertension (fourth revision). Sistemnye Gipertenzii 2010; (3): 5–6. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5–6).
2. Hansson L, Zanchetti A, Carruthers S et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755–2.
3. Chazova I.E., Martynyuk T.V., Kolos I.P. The first results of the Russian program STRATEGIYA in patients with hypertension: evaluation of noliprel with insufficient control of blood pressure. Consilium medicum 2007; 9(5): 5–0. Russian (Чазова И.Е., Мартынюк Т.В., Колос И.П. Первые результаты Российской программы СТРАТЕГИЯ у пациентов с артериальной гипертензией: оценка эффективности Нолипрела при недостаточном контроле артериального давления. Consilium medicum 2007; 9(5): 5–0).
4. Dahlof B, Sever PS, Poulter NR. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–06.
5. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease The International Verapamil- Trandolapril Study (INVEST): A Randomized Controlled Trial JAMA 2003;290:2805–6.
6. Chazova I.E., Ratova L.G.. Combination therapy in patients with hypertension. Sistemnye gipertenzii 2010; 2: 6–0. Russian (Чазова И.Е., Ратова Л.Г. Комбинированная терапия у пациентов с артериальной гипертонией. Системные гипертензии 2010; 2: 6–0).
7. Bangalore S., Kamalakkannan G.,, Parkar S., Messerli FH. Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis. The American Journal of Medicine 2007; 120: 713–19.
8. Kaiser E., Axthelm C, Sieder C, Meister F. A database analysis to evaluate the risk of cardiovascular events in hypertensive patients being treated with either the single pill combination of valsartan and amlodipine or the respective free combination. Journal of Hypertension 2011; 29 (e-Suppl A): e282.
9. Dahlof B., Sever PS, Poulter NR. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial –Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentral randomized controlled trial. Lancet 2005; 366: 895–06.
10. Jamerson KA, Bakris GL, Wun CC et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417−28
11. Preobrazhenskiy D.V., Sidorenko B.A., Dedova I.S., Shaipova A.M., Tarykina E.V. Lercanidipine –a new calcium antagonist of the third generation: clinical pharmacology and experience of use in the treatment of hypertension. Russkiy Meditsinskiy Zhurnal 2006; 14(20): 1411–417. Russian (Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Шаипова А.М., Тарыкина Е.В. Лерканидипин —новый антагонист кальция третьего поколения: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Русский Медицинский Журнал 2006; 14(20): 1411–417).
12. Herbette L.G., Vecchiarelli M., Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovascul Pharmacol 1997; 29 (suppl 1): S19—24.
13. Kukes V.G., Ostroumova O.D., Starodubtsev A.K. Calcium antagonists: modern aspects of cardiology. Consilium medicum 2006; 8 (11): 113–17. Russian (Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium
14. medicum 2006; 8 (11): 113–17).
15. Chazova I.E., Ratova L.G. Combination therapy of hypertension. Moscow: Media-Medica; 2007. Russian (Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. Москва: Медиа-Медика; 2007).
16. Vestra MD, Pozza G, Mosca A. et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diab Nutr Metab 2004; 17: 259–66.
17. Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment of Mild Hypertension Study (TOMHS) final results. J Am Med Assoc 1993; 270: 713–4.
18. Bang LM, Chapman TM, Goa KL. Lercandipine –a review of its efficacy management of hypertension. Drugs 2003; 22: 2449–472.
19. Fogari R., Mugellini A., Corradi L. et al. Efficacy of lercandipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients. J Hypertens 2000; 18 (Suppl 2): S65.
20. Devereux RB, Palmieri V, Sharpe N et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation 2001;104: 1248–4.
21. Angelico P, Guarneri L, Leonardi A, Testa R. Vascular-selective effect of lercanidipine and other 1,4- dihydropyri- dines in isolated rabbit tissues. J Pharm Pharmacol 1999; 51:709–14.
22. Park J.B., Schiffrin E.L. Effects of antihypertensive therapy on hypertensive vascular disease. Curr Hypertens Rep 2000; 2(3): 280–.
23. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as addon to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006;24:185– 92.
24. Puig JG, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens 2007;21:917–4.
25. Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension. Arzneimittelforschung 2010;60:124–0.
26. Scholze J, Bramlage P, Trenkwalder P, Kreutz R. Efficacy and safety of a fixed-dosecombination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin Pharmacother (2011) 12(17): 1–.
27. Rothwell PM, Howard SC, Dolan E et al.; ASCOT-BPLA and MRC Trial Investigators. Effects of betablockers and calcium-channel blockers on within individual variability in blood pressure and risk of stroke. Lancet Neurology 2010;9:469–80.
Review
For citations:
Ostroumova O.D., Kopchenov I.I. FIXED COMBINATION OF THE CALCIUM CHANNEL BLOCKER LERCANIDIPINE AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR ENALAPRIL: POSSIBILITY OF USAGE. Rational Pharmacotherapy in Cardiology. 2013;9(2):177-182. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-2-177-182
Views: 1478
Email this article 